Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Growth Hormone
Refined ghrelin mimetic — stronger GH release than GHRP-6 with less hunger.
Peptide B
Growth Hormone
FDA-approved GHRH analog for HIV-associated lipodystrophy with potent GH-releasing activity.
Typical vial
5 mg
Typical dose
100 mcg
Half-life
~15-60 minutes
FDA status
Not FDA approved for any indication.
Typical vial
2 mg
Typical dose
1000-2000 mcg
Half-life
~26 minutes
FDA status
FDA approved. Egrifta (tesamorelin) approved November 2010 f…
GHRP-2 effects
Tesamorelin effects
GHRP-2 side effects
Tesamorelin side effects
GHRP-2 dosing ranges
GH optimization / anti-aging
100 mcg · Two to three times daily (SubQ) · 8-12 weeks
Combined with CJC-1295 (Mod GRF)
100 mcg of each · Two to three times daily · 8-12 weeks
Adult GHD diagnostic (Japan, clinical)
100 mcg IV bolus · Single dose · One-time test
Tesamorelin dosing ranges
HIV lipodystrophy (FDA approved)
2000 mcg · Once daily (SubQ) · Ongoing as prescribed
Body composition / anti-aging (off-label)
1000-2000 mcg · Once daily · 8-12 weeks
GHRP-2: Refined ghrelin mimetic — stronger GH release than GHRP-6 with less hunger. Typical dose 100 mcg. Tesamorelin: FDA-approved GHRH analog for HIV-associated lipodystrophy with potent GH-releasing activity. Typical dose 1000-2000 mcg. Both fall under the Growth Hormone category.
Stacking GHRP-2 with Tesamorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
GHRP-2 is typically dosed: Two to three times daily (SubQ) for GH optimization / anti-aging; Two to three times daily for Combined with CJC-1295 (Mod GRF); Single dose for Adult GHD diagnostic (Japan, clinical). Tesamorelin is typically dosed: Once daily (SubQ) for HIV lipodystrophy (FDA approved); Once daily for Body composition / anti-aging (off-label).
GHRP-2: Not FDA approved for any indication. Tesamorelin: FDA approved. Egrifta (tesamorelin) approved November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Egrifta SV (reformulated single-vial) approved 2019.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free